Cargando…
Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1%
PURPOSE: To compare the refractive outcome and residual accommodation with respect to various degrees of iris and skin pigmentation in hypermetropic children using 2 drops of cyclopentolate 1% (C + C) or 1 drop of cyclopentolate 1% and 1 drop of tropicamide 1% (C + T). METHODS: Two hundred fifty‐one...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298034/ https://www.ncbi.nlm.nih.gov/pubmed/34672100 http://dx.doi.org/10.1111/aos.15016 |
_version_ | 1784750610646564864 |
---|---|
author | van Minderhout, Helena M. Joosse, Maurits V. Grootendorst, Diana C. Schalij‐Delfos, Nicoline E. |
author_facet | van Minderhout, Helena M. Joosse, Maurits V. Grootendorst, Diana C. Schalij‐Delfos, Nicoline E. |
author_sort | van Minderhout, Helena M. |
collection | PubMed |
description | PURPOSE: To compare the refractive outcome and residual accommodation with respect to various degrees of iris and skin pigmentation in hypermetropic children using 2 drops of cyclopentolate 1% (C + C) or 1 drop of cyclopentolate 1% and 1 drop of tropicamide 1% (C + T). METHODS: Two hundred fifty‐one hypermetropic children were classified according to iris and skin pigmentation (light, medium, dark) and received randomized and double‐blind C + C or C + T. Refractive error (spherical equivalent, SEQ) was determined using the Retinomax‐K + 3. In 204 subjects, residual accommodation (RA) was determined using the PlusoptiX PowerRefractor. RESULTS: A linear mixed model with a light‐irided and light skin‐pigmented reference group receiving C + T (mean SEQ +3.10 ± 1.87D) indicated significant less hypermetropia in subjects with a dark iris having a medium‐ and dark‐pigmented skin in C + T, −1.02 ± 0.29 (−1.59/−0.45) and −1.53 ± 0.30 (−2.10/−0.95); and in subjects having a light‐, medium‐ and dark‐pigmented skin in C + C, −0.74 ± 0.34 (−1.41/−0.06), −1.26 ± 0.30 (−1.85/−0.66) and −1.84 ± 0.30 (−2.42/−1.26). Similar findings were present for RA. Our model with a light‐irided and light skin‐pigmented reference group receiving C + T (mean RA +0.84 ± 0.61D) indicated significantly higher RA in dark‐irided subjects with medium‐ and dark‐pigmented skin in C + T, +1.05 ± 0.19 (+0.67/+1.43) and +1.35 ± 0.20 (+0.9/+1.74), and in C + C, +1.13 ± 0.21 (+0.71/+1.55) and +1.90 ± 0.19 (+1.51/+2.28). CONCLUSIONS: We found solid evidence that skin pigmentation rather than iris pigmentation is the decisive factor for effectiveness of cycloplegics. Awareness of the limitations of cycloplegic regimens in dark‐irided/pigmented children is needed. Our study showed that cyclopentolate 1% combined with tropicamide 1% provides more accurate refractive outcomes both statistically and clinically integrating the factor skin pigmentation for dark‐irided subjects. |
format | Online Article Text |
id | pubmed-9298034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92980342022-07-21 Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1% van Minderhout, Helena M. Joosse, Maurits V. Grootendorst, Diana C. Schalij‐Delfos, Nicoline E. Acta Ophthalmol Original Articles PURPOSE: To compare the refractive outcome and residual accommodation with respect to various degrees of iris and skin pigmentation in hypermetropic children using 2 drops of cyclopentolate 1% (C + C) or 1 drop of cyclopentolate 1% and 1 drop of tropicamide 1% (C + T). METHODS: Two hundred fifty‐one hypermetropic children were classified according to iris and skin pigmentation (light, medium, dark) and received randomized and double‐blind C + C or C + T. Refractive error (spherical equivalent, SEQ) was determined using the Retinomax‐K + 3. In 204 subjects, residual accommodation (RA) was determined using the PlusoptiX PowerRefractor. RESULTS: A linear mixed model with a light‐irided and light skin‐pigmented reference group receiving C + T (mean SEQ +3.10 ± 1.87D) indicated significant less hypermetropia in subjects with a dark iris having a medium‐ and dark‐pigmented skin in C + T, −1.02 ± 0.29 (−1.59/−0.45) and −1.53 ± 0.30 (−2.10/−0.95); and in subjects having a light‐, medium‐ and dark‐pigmented skin in C + C, −0.74 ± 0.34 (−1.41/−0.06), −1.26 ± 0.30 (−1.85/−0.66) and −1.84 ± 0.30 (−2.42/−1.26). Similar findings were present for RA. Our model with a light‐irided and light skin‐pigmented reference group receiving C + T (mean RA +0.84 ± 0.61D) indicated significantly higher RA in dark‐irided subjects with medium‐ and dark‐pigmented skin in C + T, +1.05 ± 0.19 (+0.67/+1.43) and +1.35 ± 0.20 (+0.9/+1.74), and in C + C, +1.13 ± 0.21 (+0.71/+1.55) and +1.90 ± 0.19 (+1.51/+2.28). CONCLUSIONS: We found solid evidence that skin pigmentation rather than iris pigmentation is the decisive factor for effectiveness of cycloplegics. Awareness of the limitations of cycloplegic regimens in dark‐irided/pigmented children is needed. Our study showed that cyclopentolate 1% combined with tropicamide 1% provides more accurate refractive outcomes both statistically and clinically integrating the factor skin pigmentation for dark‐irided subjects. John Wiley and Sons Inc. 2021-10-20 2022-06 /pmc/articles/PMC9298034/ /pubmed/34672100 http://dx.doi.org/10.1111/aos.15016 Text en © 2021 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles van Minderhout, Helena M. Joosse, Maurits V. Grootendorst, Diana C. Schalij‐Delfos, Nicoline E. Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1% |
title | Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1% |
title_full | Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1% |
title_fullStr | Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1% |
title_full_unstemmed | Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1% |
title_short | Eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1% |
title_sort | eye colour and skin pigmentation as significant factors for refractive outcome and residual accommodation in hypermetropic children: a randomized clinical trial using cyclopentolate 1% and tropicamide 1% |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298034/ https://www.ncbi.nlm.nih.gov/pubmed/34672100 http://dx.doi.org/10.1111/aos.15016 |
work_keys_str_mv | AT vanminderhouthelenam eyecolourandskinpigmentationassignificantfactorsforrefractiveoutcomeandresidualaccommodationinhypermetropicchildrenarandomizedclinicaltrialusingcyclopentolate1andtropicamide1 AT joossemauritsv eyecolourandskinpigmentationassignificantfactorsforrefractiveoutcomeandresidualaccommodationinhypermetropicchildrenarandomizedclinicaltrialusingcyclopentolate1andtropicamide1 AT grootendorstdianac eyecolourandskinpigmentationassignificantfactorsforrefractiveoutcomeandresidualaccommodationinhypermetropicchildrenarandomizedclinicaltrialusingcyclopentolate1andtropicamide1 AT schalijdelfosnicolinee eyecolourandskinpigmentationassignificantfactorsforrefractiveoutcomeandresidualaccommodationinhypermetropicchildrenarandomizedclinicaltrialusingcyclopentolate1andtropicamide1 |